An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

• Status: Withdrawn
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chimerix
• Collaborator: Food and Drug Administration (FDA)
• Treatments: Brincidofovir

Criteria

Inclusion Criteria:

• Individuals have high-risk exposure to Ebola Virus based on CDC definitions

• Must be able to ingest, absorb and tolerate oral medication

• As appropriate, must be willing to use adequate methods of contraception during the study and at least 6 months after their last dose of BCV

Exclusion Criteria:

-